Evidence map›Paper›PMID 42312383›Full record

ArticleBritish journal of haematology2026

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.

Borja Puertas, Irene Padilla, Elena Alejo, Fe Serra-Toral, Aránzazu García-Mateo, Rosa López-López, Abelardo Bárez, José María Alonso-Alonso, Carlos Aguilar-Franco, Erik de Cabo and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Borja PuertasHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Irene PadillaHematology Department, University Hospital of León, IBILEON, León, Spain.
Elena AlejoHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Fe Serra-ToralHematology Department, University Hospital of Burgos, Burgos, Spain.
Aránzazu García-MateoHematology Department, University Hospital of Segovia, Segovia, Spain.
Rosa López-LópezHematology Department, University Hospital of Virgen del Puerto, Plasencia, Spain.
Abelardo BárezHematology Department, University Hospital Nuestra Señora de Sonsoles, Ávila, Spain.
José María Alonso-AlonsoHematology Department, Hospital Río Carrión, Palencia, Spain.
Carlos Aguilar-FrancoHematology Department, University Hospital Santa Bárbara, Soria, Spain.
Erik de CaboHematology Department, University Hospital El Bierzo, León, Spain.
Alberto Cantalapiedra-DiezHematology Department, University Hospital Rio Hortega, Valladolid, Spain.
Alfonso García-CocaHematology Department, University Clinical Hospital of Valladolid, Valladolid, Spain.
Roberto HernándezHematology Department, University Hospital Virgen de la Concha, Zamora, Spain.
Beatriz Rey-BúaHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Marta Fonseca-SantosHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Miriam López-ParraHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Lucía López-CorralHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Norma C GutiérrezHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
María Belén Vidriales-VicenteHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
José J PérezHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Verónica González-CalleHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
María-Victoria MateosHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.ORCID https://orcid.org/0000-0003-2390-1218
Fernando EscalanteHematology Department, University Hospital of León, IBILEON, León, Spain.
Juan Flores-MonteroHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Noemi PuigHematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While measurable residual disease (MRD) in bone marrow (bmMRD) is a validated surrogate biomarker in multiple myeloma (MM), the clinical relevance of MRD in the apheresis product (aMRD) remains unclear. We retrospectively analysed 422 MM patients who underwent autologous stem cell transplantation (ASCT) between 2005 and 2023 at the University Hospital of Salamanca, all evaluated for aMRD by 8-colour flow cytometry. Overall, 45 patients (10%) were aMRD+ve and 377 (90%) were aMRD-ve, with similar baseline characteristics except for a higher frequency of t(11;14) in aMRD+ve cases. Patients with responses worse than a very good partial response before apheresis were six times more likely to be aMRD+ve (odds ratio [OR] 6.6, p = 0.006), and notably, no patients with bmMRD-ve status prior to apheresis were aMRD+ve. After ASCT, patients with aMRD+ve exhibited lower rates of complete response and bmMRD-ve than patients with aMRD-ve, leading to a shorter progression-free survival (hazard ratio 1.7, p = 0.006), and aMRD+ve status was identified as an independent predictor of early relapse (OR 9.75, p = 0.007). These findings may suggest that aMRD+ve serves as a critical early biomarker to identify suboptimal treatment responses, reflecting bmMRD persistence and predicting inferior clinical outcomes.

Indexed as

Blood Component RemovalMultiple MyelomaNeoplasm, ResidualAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRetrospective StudiesTransplantation, AutologousASCTearly relapseMRD

Identifiers

PMID42312383
PMCPMC13462184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.